Cover Image
市場調查報告書

男性不孕症:開發中產品分析

Male Infertility - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 255962
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
男性不孕症:開發中產品分析 Male Infertility - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 38 Pages
簡介

所謂男性不孕症,是指男性方面沒有使可懷孕之正常女性懷孕的狀態。男性不孕症可因造精功能障礙或精子無力、射精障礙等原因造成。主要症狀有睪丸附近疼痛、紅朣、疙瘩等。主要致病原因有抽煙或喝酒、體重超重、曝露在毒素下、特定疾病(腫瘤·慢性病及其他)等。主要治療法有外科手術及荷爾蒙補充治療等。

本報告提供全球各國的男性不孕症治療用的開發中產品的開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

男性不孕症概要

治療藥的開發

  • 男性不孕症開發中產品:概要
  • 各企業開發中的男性不孕症治療藥
  • 大學/研究機關研究中的男性不孕症治療藥
  • 開發中的產品的一覽(各企業)
  • 研究中的產品的一覽(各大學/研究機關)

男性不孕症:治療藥的評估

  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

男性不孕症開發治療藥的企業

  • AlphaMab Co Ltd
  • Ferring International Center SA
  • Health Ever Bio-Tech Co Ltd
  • Navya Biologicals Pvt Ltd
  • PharmaEssentia Corp
  • TocopheRx Inc
  • Zydus Cadila Healthcare Ltd

藥物簡介

男性不孕症治療藥:開發暫停的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9690IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Infertility - Pipeline Review, H2 2017, provides an overview of the Male Infertility (Male Health) pipeline landscape.

Male infertility refers to a male's inability to achieve a pregnancy in a fertile female. Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Infertility - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Infertility (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Male Infertility - Overview
    • Male Infertility - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Male Infertility - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Male Infertility - Companies Involved in Therapeutics Development
    • Cadila Healthcare Ltd
    • Ferring International Center SA
    • Health Ever Bio-Tech Co Ltd
    • Navya Biologicals Pvt Ltd
  • Male Infertility - Drug Profiles
    • Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 5 for Infertility and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FE-999310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAM-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PKB-171 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Beta Glucosidase 2 Replacement for Gaucher's Disease and Male Infertility - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trequinsin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Male Infertility - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Male Infertility, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Male Infertility - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Male Infertility - Pipeline by Ferring International Center SA, H2 2017
  • Male Infertility - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017
  • Male Infertility - Pipeline by Navya Biologicals Pvt Ltd, H2 2017
  • Male Infertility - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Male Infertility, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top